FDA Modernization Act 2.0 allows for alternatives to animal testing

被引:159
作者
Han, Jason J. [1 ]
机构
[1] Univ Penn, Philadelphia, PA 19104 USA
关键词
D O I
10.1111/aor.14503
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
On December 29, 2022, President Biden signed into law the FDA Modernization Act 2.0. The bill essentially refutes the Federal Food, Drug, and Cosmetics Act of 1938, which mandated animal testing for every new drug development protocol. While for the past century, the mandate was intended to ensure certain quality and safety standards for drugs and medical devices, recent advancements in science have begun to offer increasingly viable alternatives to animal testing. For certain areas such as organ replacement therapies, non-animal testing may not prove to be an adequate alternative in the foreseeable future.
引用
收藏
页码:449 / 450
页数:2
相关论文
共 3 条
[1]  
[Anonymous], FED JUDG RUL NIH BRO
[2]  
[Anonymous], 2022, PETA
[3]  
Commissioner O.,, 2022, Advancing Alternative Methods at FDA